The Medicines Company Collaborates with AstraZeneca To Sell Brilinta...
The Medicines Company will collaborate with AstraZeneca to help sell Brilinta (ticagrelor), AstraZeneca’s struggling oral antiplatelet drug. The collaboration is the first stage of “a global...
View ArticleFDA Approves Generic Clopidogrels As Plavix Loses Patent Protection
For the second time in the past six months, a cardiology mainstay drug has lost patent protection and gone generic. Today the FDA announced that it had approved several generic versions of clopidogrel...
View ArticleTicagrelor Joins Clopidogrel And Prasugrel In Updated NSTEMI Guidelines
Ticagrelor (Brilinta, AstraZeneca) gains equal standing with prasugrel (Effient, Lilly) and clopdiogrel in the newly released focused update of the ACCF/AHA guidelines for unstable angina and...
View ArticleUK Politician Urges More Use Of Ticagrelor To Preserve AstraZeneca Jobs In UK
Use it or lose it. A UK politician is urging the National Health Service (NHS) to increase use of the antiplatelet drug ticagrelor (trade name Brilinta in the US, Brilique and Possia in the EU) in...
View ArticleUS Department Of Justice Ends Investigation Of AstraZenca Trial
AstraZeneca announced today that the US Department of Justice has ended its investigation into alleged misconduct associated with the pivotal PLATO trial. The company said it had fully cooperated with...
View ArticleAstraZeneca Drug Improves Outcomes After Heart Attacks
For the first time a very large trial has shown that dual antiplatelet therapy (DAPT) improves cardiovascular outcomes when given to patients one to three years after a heart attack. Because it has...
View ArticleAstraZeneca Drug ‘Approaching The Point Of Diminishing Returns’
After a heart attack (myocardial infarction or MI) patients remain at high risk for recurrent events. The precise role of blood thinning with dual antiplatelet therapy to lower this risk has been the...
View ArticleTicagrelor No Better Than Clopidogrel In Peripheral Artery Disease
AstraZeneca announces top-line results from EUCLID trial ahead of the AHA. Ticagrelor is no better than clopidogrel in patients who have peripheral artery disease, a large new study will show. On...
View Article
